Have a personal or library account? Click to login
Opportunistic Candida Infections in Critical COVID-19 Patients Cover

Opportunistic Candida Infections in Critical COVID-19 Patients

Open Access
|Sep 2022

References

  1. Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, Hoenigl M. COVID-19-associated candidiasis (CAC): An underestimated complication in the absence of ımmunological predispositions? J Fungi (Basel). 2020 Oct 8;6(4):211. https://doi.org/10.3390/jof6040211
  2. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, Cornely OA, S Perlin D, Lass-Flörl C, Hoenigl M. COVID- 19 associated pulmonary aspergillosis (CAPA) – from immunology to treatment. J Fungi (Basel). 2020a;6(2):91. https://doi.org/10.3390/jof6020091
  3. Arastehfar A, Shaban T, Zarrinfar H, Roudbary M, Ghazanfari M, Hedayati MT, Sedaghat A, Ilkit M, Najafzadeh MJ, Perlin DS. Candidemia among Iranian patients with severe COVID-19 admitted to ICUs. J Fungi (Basel). 2021 Apr 08;7(4):280. https://doi.org/10.3390/jof7040280
  4. Bastos GAN, Azambuja AZ, Polanczyk CA, Gräf DD, Zorzo IW, Maccari JG, Haygert LS, Nasi LA, Gazzana MB, Bessel M, et al. Clinical characteristics and predictors of mechanical ventilation in patients with COVID- 19 hospitalized in Southern Brazil. Rev Bras Ter Intensiva. 2020 Oct-Dec;32(4):487–492. https://doi.org/10.5935/0103-507X.20200082
  5. Binelli CA, Moretti ML, Assis RS, Sauaia N, Menezes PR, Ribeiro E, Geiger DCP, Mikami Y, Miyaji M, Oliveira MS, et al. Investigation of the possible association between nosocomial candiduria and candidaemia. Clin Microbiol Infect. 2006 Jun;12(6):538–543. https://doi.org/10.1111/j.1469-0691.2006.01435.x
  6. Bishburg E, Okoh A, Nagarakanti SR, Lindner M, Migliore C, Patel P. Fungemia in COVID- 19 ICU patients, a single medical center experience. J Med Virol. 2021 May;93(5):2810–2814. https://doi.org/10.1002/jmv.26633
  7. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg Infect Dis. 2020 Nov;26(11):2694–2696. https://doi.org/10.3201/eid2611.203504
  8. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard – Third edition. CLSI document M27-A. Wayne (USA): Clinical and Laboratory Standards Institute; 2008.
  9. Coşkun AS, Durmaz ŞÖ. Fungal infections in COVID- 19 intensive care patients. Pol J Microbiol. 2021 Sep 01;70(3):395–400. https://doi.org/10.33073/pjm-2021-039
  10. da Silva RB, Neves RP, Hinrichsen SL, de Lima-Neto RG. Candidemia in a public hospital in Northeastern Brazil: Epidemiological features and risk factors in critically ill patients. Rev Iberoam Micol. 2019 Oct-Dec;36(4):181–185. https://doi.org/10.1016/j.riam.2019.06.003
  11. Drogari-Apiranthitou M, Anyfantis I, Galani I, Kanioura L, Daikos GL, Petrikkos G. Association between candiduria and candidemia: A clinical and molecular analysis of cases. Mycopathologia. 2017 Dec; 182(11–12):1045–1052. https://doi.org/10.1007/s11046-017-0180-2
  12. Eggimann P, Que YA, Revelly JP, Pagani JL. Preventing invasive candida infections. Where could we do better? J Hosp Infect. 2015 Apr;89(4):302–308. https://doi.org/10.1016/j.jhin.2014.11.006
  13. Esposito S, De Simone G, Boccia G, De Caro F, Pagliano P. Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist. 2017 Sep;10:204–212. https://doi.org/10.1016/j.jgar.2017.06.013
  14. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009 May;37(5):1649–1654. https://doi.org/10.1097/CCM.0b013e31819def97
  15. Kasper L, König A, Koenig PA, Gresnigt MS, Westman J, Drummond RA, Lionakis MS, Groß O, Ruland J, Naglik JR, et al. The fungal peptide toxin candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat Commun. 2018 Dec;9(1):4260. https://doi.org/10.1038/s41467-018-06607-1
  16. Kauffman CA. Candiduria. Clin Infect Dis. 2005 Sep 15;41 Supplement_6:S371–S376. https://doi.org/10.1086/430918
  17. Kayaaslan B, Eser F, Kaya Kalem A, Bilgic Z, Asilturk D, Hasanoglu I, Ayhan M, Tezer Tekce Y, Erdem D, Turan S, et al. Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients. Mycoses. 2021 Sep;64(9):1083–1091. https://doi.org/10.1111/myc.13332
  18. Kayaaslan B, Kaya Kalem A, Asilturk D, Kaplan B, Dönertas G, Hasanoglu I, Eser F, Korkmazer R, Oktay Z, Ozkocak Turan I, et al. Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients. Mycoses. 2022 May;65(5):508–516. https://doi.org/10.1111/myc.13431
  19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985; 13(10):818–829. https://doi.org/10.1097/00003246-198510000-00009
  20. Kokkoris S, Papachatzakis I, Gavrielatou E, Ntaidou T, Ischaki E, |Malachias S, Vrettou C, Nichlos C, Kanavou A, Zervakis D, et al. ICU-acquired bloodstream infections in critically ill patients with COVID-19. J Hosp Infect. 2021 Jan;107:95–97. https://doi.org/10.1016/j.jhin.2020.11.009
  21. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
  22. Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Li Voti R, Muccini C, Ripa M, Canetti D, Castiglioni B, Oltolini C, et al.; COVID-BioB Study Group. Candidemia in coronavirus disease 2019 (COVID-19) patients: Incidence and characteristics in a prospective cohort compared with historical Non-COVID-19 Controls. Clin Infect Dis. 2021 Nov 02;73(9):e2838–e2839. https://doi.org/10.1093/cid/ciaa1594
  23. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12(1):204. https://doi.org/10.1186/cc6212
  24. Mermutluoglu C, Deveci O, Dayan S, Aslan E, Bozkurt F, Tekin R. Antifungal susceptibility and risk factors in patients with candidemia. Eurasian J Med. 2016 Jan 19;48(3):199–203. https://doi.org/10.5152/eurasianmed.2016.0021
  25. Niyas VK, Rahulan SD, Arjun R, Sasidharan A. ICU-acquired candidemia in COVID-19 patients: An experience from a tertiary care hospital in Kerala, South India. Indian J Crit Care Med. 2021 Oct;25(10):1207–1208. https://doi.org/10.5005/jp-journals-10071-23980
  26. Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC, Nouér SA. Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic. Mycoses. 2021 Feb; 64(2):152–156. https://doi.org/10.1111/myc.13225
  27. Omrani AS, Koleri J, Ben Abid F, Daghfel J, Odaippurath T, Peediyakkal MZ, Baiou A, Sarsak E, Elayana M, Kaleeckal A, et al. Clinical characteristics and risk factors for COVID-19-associated Candidemia. Med Mycol. 2021 Dec 03;59(12):1262–1266. https://doi.org/10.1093/mmy/myab056
  28. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1–e50. https://doi.org/10.1093/cid/civ933
  29. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 Nov 01;71(9):2459–2468. https://doi.org/10.1093/cid/ciaa530
  30. Revankar SG, Hasan MS, Revankar VS, Sobel JD. Long-term follow-up of patients with candiduria. Eur J Clin Microbiol Infect Dis. 2011 Feb;30(2):137–140. https://doi.org/10.1007/s10096-010-1061-5
  31. Rotondo JC, Bononi I, Puozzo A, Govoni M, Foschi V, Lanza G, Gafà R, Gaboriaud P, Touzé FA, Selvatici R, et al. Merkel cell carcinomas arising in autoimmune disease affected patients treated with biologic drugs, including anti-TNF. Clin Cancer Res. 2017 Jul 15;23(14):3929–3934. https://doi.org/10.1158/1078-0432.CCR-16-2899
  32. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res. 2020 Aug;51(6):595–597. https://doi.org/10.1016/j.arcmed.2020.05.009
  33. Seagle EE, Jackson BR, Lockhart SR, Georgacopoulos O, Nunnally NS, Roland J, Barter DM, Johnston HL, Czaja CA, Kayalioglu H, et al. The landscape of candidemia during the coronavirus disease 2019 (COVID-19) Pandemic. Clin Infect Dis. 2022 Mar 09;74(5):802–811. https://doi.org/10.1093/cid/ciab562
  34. Segrelles-Calvo G, de S Araújo GR, Llopis-Pastor E, Carrillo J, Hernández-Hernández M, Rey L, Melean NR, Escribano I, Antón E, Zamarro C, et al. Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors. Respir Med. 2021 Nov;188:106619. https://doi.org/10.1016/j.rmed.2021.106619
  35. Vallabhaneni S, Chiller TM. Fungal infections and new biologic therapies. Curr Rheumatol Rep. 2016 May; 18(5):29. https://doi.org/10.1007/s11926-016-0572-1
  36. van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID- 19 patients: A systematic review and meta-analysis on clinical outcomes. Crit Care. 2020 Dec; 24(1):696. https://doi.org/10.1186/s13054-020-03400-9
  37. Villanueva-Lozano H, Treviño-Rangel RJ, González GM, Ramírez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC, Guajardo-Lara CE, Gaona-Chávez N, Castilleja-Leal F, Torre-Amione G, et al. Outbreak of Candida auris infection in a COVID- 19 hospital in Mexico. Clin Microbiol Infect. 2021 May;27(5):813–816. https://doi.org/10.1016/j.cmi.2020.12.030
  38. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309–317. https://doi.org/10.1086/421946
  39. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID- 19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954
DOI: https://doi.org/10.33073/pjm-2022-036 | Journal eISSN: 2544-4646 | Journal ISSN: 1733-1331
Language: English
Page range: 411 - 419
Submitted on: May 23, 2022
Accepted on: Jul 19, 2022
Published on: Sep 24, 2022
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Mıne Altinkaya Çavuş, Hafıze Sav, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.